News

The label now includes evidence from newly diagnosed patients, widening confidence before revealing commercial uptake.

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six. Three peers grew faster and returned less, Eli Lilly among them. The price is a bet that the rest of the business keeps growing once shrinking STELARA sales stop dragging on the total.

Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.

Moderna Inc. (NASDAQ:MRNA) rebounded to a new three-year high on Monday, as investors began positioning their portfolios ahead of two upcoming health conferences, one of which will be held on Wednesday, September 23. In intra-day trading, the stock jumped to a new record high of $176.86 before paring gains to hover just above the $174 […]

Moderna’s personalized cancer vaccine, intismeran autogene, will feature at the annual meeting of the European Society for Medical Oncology.

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual Phase 3 melanoma data remains unseen. Here is why the scheduling alone is moving markets and what it signals about what that dataset might show.

OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.

Merck (MRK) closed at $147.17 in the latest trading session, marking a +1.56% move from the prior day.

Moderna President Stephen Hoge says the company remains on track for its longtime goal of reaching cash breakeven by 2028.

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly what kind of bet the market is actually making.

With $124 trillion set to move in the Great Wealth Transfer, these wealth-building stocks can help you leave something behind for your kids.

Merck is beating the market year-to-date after a jump on positive Phase 3 data, while paying an annualized dividend of about $3.40 for a yield above 2.3%.

Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is clean but short. That record asks for the better part of a year and more pain before it pays. And this fall is not the kind of fall that record is built on.

PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.

Income seekers can't go wrong with these companies.

Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped into the red, and no announcement, trial readout, or analyst call explains why.

A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.

Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether this pharmaceutical giant still has meaningful upside left.

Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.

Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.

Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.

Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.

Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.

Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.

Merck KGaA (NYSE:MRK) shares rose 1. 7% to €141.

Moderna Inc. (NASDAQ:MRNA) saw its share price soar by 156 percent in August—making it the highest-gaining stock for the month—driven primarily by the strong clinical trial results of its therapy candidate for melanoma, supported by a recent regulatory approval for its updated COVID-19 vaccines. It can be recalled that Moderna and Merck recently partnered for […]

Moderna stock surged 158% in August to lead the S&P 500, while Edison International plunged 27% to rank last in the index.